Gt Biopharma Stock Probability Of Bankruptcy

GTBP Stock  USD 2.74  0.08  2.84%   
GT Biopharma's chance of distress is over 65% at this time. It has high odds to experience some financial crisis in the next few years. Probability of distress prediction helps decision makers evaluate GT Biopharma's chance of financial distress in relation to its going-concern outlook and evaluation. All items used in analyzing the odds of distress are taken from the GTBP balance sheet, as well as cash flow and income statements available from the company's most recent filings. Check out GT Biopharma Piotroski F Score and GT Biopharma Altman Z Score analysis.
To learn how to invest in GTBP Stock, please use our How to Invest in GT Biopharma guide.
  
As of 12/04/2024, Market Cap is likely to drop to about 24.1 M. In addition to that, Enterprise Value is likely to drop to about 19.4 M

GT Biopharma Company probability of distress Analysis

GT Biopharma's Probability Of Bankruptcy is a relative measure of the likelihood of financial distress. For stocks, the Probability Of Bankruptcy is the normalized value of Z-Score. For funds and ETFs, it is derived from a multi-factor model developed by Macroaxis. The score is used to predict the probability of a firm or a fund experiencing financial distress within the next 24 months. Unlike Z-Score, Probability Of Bankruptcy is the value between 0 and 100, indicating the firm's actual probability it will be financially distressed in the next 2 fiscal years.

Probability Of Bankruptcy

 = 

Normalized

Z-Score

More About Probability Of Bankruptcy | All Equity Analysis

Current GT Biopharma Probability Of Bankruptcy

    
  Over 74%  
Most of GT Biopharma's fundamental indicators, such as Probability Of Bankruptcy, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, GT Biopharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Our calculation of GT Biopharma probability of bankruptcy is based on Altman Z-Score and Piotroski F-Score, but not limited to these measures. To be applied to a broader range of industries and markets, we use several other techniques to enhance the accuracy of predicting GT Biopharma odds of financial distress. These include financial statement analysis, different types of price predictions, earning estimates, analysis consensus, and basic intrinsic valuation. Please use the options below to get a better understanding of different measures that drive the calculation of GT Biopharma financial health.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of GT Biopharma. If investors know GTBP will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about GT Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(7.39)
Return On Assets
(0.61)
Return On Equity
(1.31)
The market value of GT Biopharma is measured differently than its book value, which is the value of GTBP that is recorded on the company's balance sheet. Investors also form their own opinion of GT Biopharma's value that differs from its market value or its book value, called intrinsic value, which is GT Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because GT Biopharma's market value can be influenced by many factors that don't directly affect GT Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between GT Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if GT Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, GT Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

GTBP Probability Of Bankruptcy Driver Correlations

Understanding the fundamental principles of building solid financial models for GT Biopharma is extremely important. It helps to project a fair market value of GTBP Stock properly, considering its historical fundamentals such as Probability Of Bankruptcy. Since GT Biopharma's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of GT Biopharma's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of GT Biopharma's interrelated accounts and indicators.
0.97-0.21-0.030.15-0.22-0.03-0.13-0.220.49-0.140.32-0.09-0.030.23-0.220.140.070.040.06
0.97-0.34-0.030.17-0.430.01-0.05-0.350.35-0.070.14-0.030.020.32-0.340.140.150.040.02
-0.21-0.340.04-0.430.63-0.58-0.410.940.24-0.210.73-0.2-0.65-0.560.93-0.08-0.89-0.40.22
-0.03-0.030.04-0.73-0.01-0.680.37-0.170.220.06-0.170.35-0.63-0.76-0.160.97-0.11-0.280.44
0.150.17-0.43-0.73-0.140.93-0.07-0.2-0.06-0.07-0.14-0.280.910.82-0.2-0.620.590.75-0.39
-0.22-0.430.63-0.01-0.14-0.18-0.340.630.48-0.230.67-0.23-0.24-0.470.6-0.03-0.37-0.040.16
-0.030.01-0.58-0.680.93-0.180.13-0.3-0.250.14-0.38-0.080.980.79-0.3-0.60.680.73-0.35
-0.13-0.05-0.410.37-0.07-0.340.13-0.32-0.330.83-0.620.880.18-0.15-0.280.290.210.330.22
-0.22-0.350.94-0.17-0.20.63-0.3-0.320.17-0.10.67-0.16-0.42-0.411.0-0.28-0.82-0.160.26
0.490.350.240.22-0.060.48-0.25-0.330.17-0.280.55-0.17-0.24-0.170.140.360.0-0.090.15
-0.14-0.07-0.210.06-0.07-0.230.140.83-0.1-0.28-0.460.950.160.01-0.07-0.040.020.03-0.02
0.320.140.73-0.17-0.140.67-0.38-0.620.670.55-0.46-0.46-0.45-0.290.65-0.16-0.62-0.190.18
-0.09-0.03-0.20.35-0.28-0.23-0.080.88-0.16-0.170.95-0.46-0.04-0.19-0.130.250.0-0.060.1
-0.030.02-0.65-0.630.91-0.240.980.18-0.42-0.240.16-0.45-0.040.81-0.42-0.540.760.71-0.37
0.230.32-0.56-0.760.82-0.470.79-0.15-0.41-0.170.01-0.29-0.190.81-0.41-0.650.610.33-0.59
-0.22-0.340.93-0.16-0.20.6-0.3-0.281.00.14-0.070.65-0.13-0.42-0.41-0.27-0.83-0.160.27
0.140.14-0.080.97-0.62-0.03-0.60.29-0.280.36-0.04-0.160.25-0.54-0.65-0.270.03-0.230.4
0.070.15-0.89-0.110.59-0.370.680.21-0.820.00.02-0.620.00.760.61-0.830.030.5-0.3
0.040.04-0.4-0.280.75-0.040.730.33-0.16-0.090.03-0.19-0.060.710.33-0.16-0.230.50.16
0.060.020.220.44-0.390.16-0.350.220.260.15-0.020.180.1-0.37-0.590.270.4-0.30.16
Click cells to compare fundamentals
The Probability of Bankruptcy SHOULD NOT be confused with the actual chance of a company to file for chapter 7, 11, 12, or 13 bankruptcy protection. Macroaxis simply defines Financial Distress as an operational condition where a company is having difficulty meeting its current financial obligations towards its creditors or delivering on the expectations of its investors. Macroaxis derives these conditions daily from both public financial statements as well as analysis of stock prices reacting to market conditions or economic downturns, including short-term and long-term historical volatility. Other factors taken into account include analysis of liquidity, revenue patterns, R&D expenses, and commitments, as well as public headlines and social sentiment.
Competition

Based on the latest financial disclosure, GT Biopharma has a Probability Of Bankruptcy of 74%. This is 70.94% higher than that of the Biotechnology sector and 34.94% higher than that of the Health Care industry. The probability of bankruptcy for all United States stocks is 85.79% lower than that of the firm.

GTBP Probability Of Bankruptcy Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses GT Biopharma's direct or indirect competition against its Probability Of Bankruptcy to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of GT Biopharma could also be used in its relative valuation, which is a method of valuing GT Biopharma by comparing valuation metrics of similar companies.
GT Biopharma is currently under evaluation in probability of bankruptcy category among its peers.

GT Biopharma Main Bankruptcy Drivers

201920202021202220232024 (projected)
Return On Assets(102.97)(5.58)(1.82)(1.23)(0.54)(0.51)
Net Debt13.3M21.0M(8.9M)(5.5M)(1.0M)(970.0K)
Total Current Liabilities19.7M35.1M10.3M4.9M6.6M6.9M
Total Assets396K5.7M32.2M16.7M14.1M13.2M
Total Current Assets274K5.7M32.2M16.6M14.1M14.8M
Total Cash From Operating Activities(3.7M)(7.3M)(15.6M)(15.2M)(8.9M)(8.4M)

GT Biopharma ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, GT Biopharma's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to GT Biopharma's managers, analysts, and investors.
Environmental
Governance
Social

GTBP Fundamentals

About GT Biopharma Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze GT Biopharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of GT Biopharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of GT Biopharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Pair Trading with GT Biopharma

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if GT Biopharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in GT Biopharma will appreciate offsetting losses from the drop in the long position's value.

Moving against GTBP Stock

  0.78ME 23Andme HoldingPairCorr
  0.71A Agilent TechnologiesPairCorr
  0.65DOMH Dominari HoldingsPairCorr
  0.58VALN Valneva SE ADRPairCorr
  0.55DRMA Dermata TherapeuticsPairCorr
The ability to find closely correlated positions to GT Biopharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace GT Biopharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back GT Biopharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling GT Biopharma to buy it.
The correlation of GT Biopharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as GT Biopharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if GT Biopharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for GT Biopharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Additional Tools for GTBP Stock Analysis

When running GT Biopharma's price analysis, check to measure GT Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy GT Biopharma is operating at the current time. Most of GT Biopharma's value examination focuses on studying past and present price action to predict the probability of GT Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move GT Biopharma's price. Additionally, you may evaluate how the addition of GT Biopharma to your portfolios can decrease your overall portfolio volatility.